Status:
WITHDRAWN
A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.
Lead Sponsor:
Janssen-Ortho Inc., Canada
Conditions:
Anemia
Blood Transfusion
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine an effective dose of epoetin alfa to be administered prior to surgery, to decrease the need for blood transfusions during hip replacement. Epoetin alfa is a g...
Detailed Description
Major surgical procedures may require blood transfusions both during and after the operation. Agents that can increase the rate of red blood cell production would reduce the need for blood transfusion...
Eligibility Criteria
Inclusion
- Patients scheduled for first-time hip replacement surgery
- having no major medical conditions
- having a hemoglobin level of 98 - 137 grams per liter
- having adequate iron stores
- not participating in a self-donated blood program
Exclusion
- Patients with a history of rheumatoid arthritis, blood disorders, recent bleeding episodes or an iron deficiency
- or having a history of seizures or uncontrolled high blood pressure (diastolic blood pressure \> 100 mmHg)
Key Trial Info
Start Date :
May 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 1999
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00269971
Start Date
May 1 1996
End Date
April 1 1999
Last Update
September 20 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.